Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$3.17 - $6.17 $424,463 - $826,163
-133,900 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$4.16 - $13.72 $482,976 - $1.59 Million
-116,100 Reduced 46.44%
133,900 $722,000
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $1.46 Million - $2.49 Million
135,200 Added 117.77%
250,000 $3.38 Million
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $1.5 Million - $2.16 Million
114,800 New
114,800 $2.06 Million
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $2.48 Million - $3.82 Million
-150,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $2.53 Million - $3.52 Million
150,000 New
150,000 $3.47 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $169M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.